When and Where
Print your Invitation
Travelling / Transportation Info
Mark Your Calendar
Speakers / Posters Registration (Abstracts Submission)
Submit a Workshop
Become a Sponsor / Partner
Join MEMBS Committee
This page will be available by 1 August 2018
This page will be available by 1st October 2018
Dr. Ena Wang
Research Chief of Transnational Medicine
Sidra Medical and Research Center
Ena Wang (MD) is the Division Chief of Translational Medicine at Sidra Medical and Research Center, She was appointed to the role in February, 2014. She leads programs focused on the study of genetic disorder, prenatal care, immunologic disorders and cancer by applying cutting edge technologies to help advance cellular therapy, gene therapy and regenerative medicine. Dr. Wang is also holds a full time faculty appointment with Weill Cornell Medical College in Qatar.
Prior to joining Sidra, Dr. Wang was Acting Chief of Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center at the National Institutes of Health (NIH). She was also the Associated Director of Trans NIH Center for Human Immunology, Omic Facility Head at the NIH and Director of Molecular Science in Department of Transfusion Medicine (DTM), Clinical Center, NIH. She was also Adjunct Professor Peking Union Medical College, Beijing, China; Adjunct Professor Shanghai Medical College, Fudan University, Shanghai China, and Adjunct Professor Southern Medical University, Guangzhou, China. Earlier in her career she was Cancer Research Fellow – Surgery Branch, National Cancer Institute, NIH and Assistant Research Scientist, Arizona Cancer Center, University of Arizona, Tucson, Arizona.
The focus of Dr. Wang’s research is the identification of genetic traits in humans that could explain the relationship between pathogens and the host with a particular interest in cancer and chronic infections. This spans the analysis of germ line characteristics that could explain the weight of the genetic background of the host in modulating disease evolution as well as the analysis of genetic alterations of cancer cells or pathogens in time that may affect disease outcome independent of the host’s response. Her work, which has been published widely in peer-reviewed journals, has focused extensively on the evolutionary variation of cancer during its natural evolution or in response to therapy and developed technologies for the real-time analysis of evolving cancer phenotypes ex vivo in patients with melanoma and other cancers.
Dr. Wang obtained her medical degree from Hebei Medical University, Shijiazhuang, Hebei Province, China and her Master of Medicine from Shanghai Medical University (Fudan University), Shanghai, China. She is a member of the American Society for Cell Biology, the American Society of Histocompatibility and Immunogenetics and the International Society for Biological Therapy of Cancer. She has held editorial positions with medical journals including Journal of Translational Medicine (a BioMed Central Journal), Current Immunology Reviews, Genetic Medicine, Immunotherapy, BMC Immunology and Clinical and Translational Medicine. She has acted as reviewing editor for Nucleic Acid Research, Genome, Genomics, Biotechniques, Nature Biotechnology, Biomolecular Engineering, Physiological Genomics, Journal of Biotechnology and participated in the Review Editorial Board of Frontiers in Tumor Immunity.